ClinicalTrials.Veeva

Menu

A Study to Observe Treatment Patterns and Outcomes in Participants in Saudi Arabia With Human Epidermal Growth Factor Receptor 2 (HER2-Positive) Unresectable Locally Advanced or Metastatic Breast Cancer (LA/mBC)

Roche logo

Roche

Status

Terminated

Conditions

Metastatic Breast Cancer

Treatments

Other: No intervention

Study type

Observational

Funder types

Industry

Identifiers

NCT02611310
ML29618

Details and patient eligibility

About

This is a prospective, national, multicenter, non-interventional study designed to enroll participants who have an initial diagnosis of unresectable LA/mBC made up to 6 months prior to registry enrollment. These participants will be prospectively followed for at least 5 years after study enrollment to evaluate their anti-cancer treatments. Data on participants' previous anti-cancer treatments for breast cancer will be collected retrospectively at study entry.

Enrollment

15 patients

Sex

All

Ages

18+ years old

Volunteers

No Healthy Volunteers

Inclusion criteria

  • Initially diagnosed with HER2-positive unresectable LA/mBC no more than 6 months prior to enrollment
  • Able to comply with the study protocol

Exclusion criteria

None

Trial design

15 participants in 1 patient group

Participants with HER2-positive unresectable LA/mBC
Treatment:
Other: No intervention

Trial contacts and locations

3

Loading...

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2024 Veeva Systems